CSANZ 2020

Questions are being raised about the benefit of high sensitivity cardiac troponin (hs-cTnT) as part of a rapid 0/1-hour MI rule out protocol for patients with suspected ACS  following negative results from 12 month follow up data of the...

Questions are being raised about the benefit of high sensitivity cardiac troponin (hs-cTnT) as part of a rapid 0/1-hour...

The landmark findings of the ISCHEMIA trial favouring conservative therapy for stable coronary artery disease (CAD) are at risk of being overlooked because of the COVID-19 pandemic, according to a panel discussion at CSANZ 2020. The study results, first released...

The landmark findings of the ISCHEMIA trial favouring conservative therapy for stable coronary artery disease (CAD) are at risk of...

With SGLT2 inhibitors now joining the mainstream of therapies for heart failure, it’s time to look at other novel approaches such as intravenous iron, vericiguat and omecamtiv mercarbil, according to an international expert. Speaking at CSANZ 2020 virtual meeting, Professor John...

With SGLT2 inhibitors now joining the mainstream of therapies for heart failure, it’s time to look at other novel approaches...